A specialized gene editing system designed by scientists at the Lewis Katz School of Medicine at Temple University is paving the way to an eventual cure for patients infected with HIV, the virus that causes AIDS. In a study published online this month in the Nature journal, Scientific Reports, the researchers show that they can both effectively and safely eliminate the virus from the DNA of human cells grown in culture.
According to senior investigator on the new study, Kamel Khalili, PhD, Laura H. Carnell Professor and Chair of the Department of Neuroscience, Director of the Center for Neurovirology, and Director of the Comprehensive NeuroAIDS Center at the Lewis Katz School of Medicine at Temple University (LKSOM), “Antiretroviral drugs are very good at controlling HIV infection. But patients on antiretroviral therapy who stop taking the drugs suffer a rapid rebound in HIV replication.” The presence of numerous copies of HIV weakens the immune system and eventually causes acquired immune deficiency syndrome, or AIDS.
Curing HIV/AIDS – which has claimed the lives of more than 25 million people since it was first discovered in the 1980s – is the ultimate goal in HIV research. But eliminating the virus after it has become integrated into CD4+ T-cells, the cells primarily infected with HIV, has proven difficult. Recent attempts have focused on intentionally reactivating HIV, aiming to stimulate a robust immune response capable of eradicating the virus from infected cells. However, to date, none of these “shock and kill” approaches has been successful.
Dr. Khalili and colleagues decided to try a different approach, specifically targeting HIV-1 proviral DNA (the integrated viral genome) using uniquely tailored gene editing technology. Their system includes a guide RNA that specifically locates HIV-1 DNA in the T-cell genome, and a nuclease enzyme, which cuts the strands of T-cell DNA. Once the nuclease has edited out the HIV-1 DNA sequence, the loose ends of the genome are reunited by the cell’s own DNA repair machinery.
In previous work, Dr. Khalili’s team had demonstrated the ability of their technology to snip out HIV-1 DNA from human cell lines. In their latest study, however, they concentrated on latently and productively infected CD4+ T cells to show not only that the technology eliminates the virus from cells but also that its persistent presence in HIV-1-eradicated cells actually protects them against reinfection. More importantly, they carried their work over to ex vivo experiments, in which T-cells from patients infected with HIV were grown in cell culture, showing that treatment with the gene editing system can suppress viral replication and dramatically reduce viral load in patient cells.
In another major component of the study, Dr. Khalili’s team addressed questions about off-target effects and toxicity. Using an approach known as ultra-deep whole-genome sequencing, which is considered the gold standard for genomic assessment, the researchers analyzed the genomes of HIV-1-eradicated cells for mutations in genes outside the region targeted by the guide RNA. Their analyses ruled out off-target effects on genes, including potential collateral effects on cellular gene expression. Studies of cell viability and proliferation showed that HIV-1-eradicated cells were growing and functioning normally.
“The findings are important on multiple levels,” Dr. Khalili said. “They demonstrate the effectiveness of our gene editing system in eliminating HIV from the DNA of CD4 T-cells and, by introducing mutations into the viral genome, permanently inactivating its replication. Further, they show that the system can protect cells from reinfection and that the technology is safe for the cells, with no toxic effects.”
“These experiments had not been performed previously to this extent,” he added. “But the questions they address are critical, and the results allow us to move ahead with this technology.”
The Latest on: HIV/AIDS
via Google News
The Latest on: HIV/AIDS
- US$ 64 million to respond to HIV, TB and malaria in Congoon March 1, 2021 at 7:11 pm
Download logo The Global Fund to Fight AIDS, Tuberculosis and Malaria, the Government of Congo and health partners have announced two new grants worth more than US$ 64 million to strengthen prevention ...
- Seattle's AIDS Memorial Pathway Continues to Bloomon March 1, 2021 at 3:24 pm
Amidst all the construction and Honey Buckets on the Broadway mixed-used development and plaza just above the Capitol Hill Link station, public art is quietly blooming. As part of the AIDS Memorial ...
- Healthwatch 16: HIV and AIDSon March 1, 2021 at 1:16 pm
Planned Parenthood Keystone wants people to know what's out there to help in the fight against HIV and AIDS. "We know that HIV and Aids are still very highly stigmatized. We also know that rates of ...
- New Mexico attorney general files lawsuit against manufacturers of antiretroviral HIV/AIDS treatment drugson February 25, 2021 at 10:05 am
Attorney General Hector Balderas has filed a lawsuit in the First Judicial District Court of New Mexico against manufacturers of antiretroviral HIV and AIDS treatment ...
- HIV/AIDs Diagnostics Market : Industry Outlook By Drivers, Restraints | By Kenneth Researchon February 24, 2021 at 5:18 am
Such factors are anticipated to drive the growth of the HIV/AIDS DIAGNOSTICS MARKET during the forecast period. Request For The Sample Report Here: Global HIV/AIDs Diagnostics Market is valued ...
- University of Houston gets $5 million to combat HIV/AIDs epidemic in the Southon February 23, 2021 at 10:24 pm
The University of Houston has received $5 million to continue its work in combating challenges that contribute to the HIV/AIDS epidemic in the South. Biopharmaceutical company Gilead Sciences donated ...
- UH receives funding from Gilead Sciences to fight against HIV/AIDS epidemicon February 22, 2021 at 5:58 pm
A University of Houston Graduate College of Social Work research center working to eradicate the underlying serious and systemic challenges that contribute to the HIV/AIDS epidemic in the Southern ...
- UH receives $5 million to combat HIV/AIDS epidemicon February 22, 2021 at 1:14 pm
A new $5 million grant from Gilead Sciences, Inc. extends the University of Houston Graduate College of Social Work's effort to eradicate the underlying serious and systemic challenges that contribute ...
- Wake Forest Divinity gets $5 million grant to help combat HIV/AIDSon February 22, 2021 at 6:04 am
The grant from Gilead Sciences will bring Wake Forest into Gilead’s 10-year, $100 million COMPASS Initiative that already includes centers at Emory University’s Rollins School of Public Health, the ...
- How 'It’s a Sin' Resonates With What I Saw of HIV/AIDS Growing Up in 1980s Zimbabweon February 19, 2021 at 8:39 am
Takudzwa Mukiwa from UK HIV/AIDS charity Terrence Higgins Trust writes on the stigma he saw growing up in Zimbabwe, and the raw power of TV show 'It's a Sin'.
via Bing News